Skip Navigation


International Immunology Advance Access originally published online on February 20, 2007
International Immunology 2007 19(4):477-486; doi:10.1093/intimm/dxm012
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
19/4/477    most recent
dxm012v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Khan, N.
Right arrow Articles by Mukhopadhyay, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Khan, N.
Right arrow Articles by Mukhopadhyay, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Japanese Society for Immunology. 2007. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org

Anti-B7-1/B7-2 antibody elicits innate-effector responses in macrophages through NF-{kappa}B-dependent pathway

Nooruddin Khan1, Sheikh Ghousunnissa1, SenthilKumar M. Jegadeeswaran1, Dorairajan Thiagarajan2, Seyed E. Hasnain1,3,4 and Sangita Mukhopadhyay1

1 Laboratory of Molecular Cell Biology Center for DNA Fingerprinting and Diagnostics, Hyderabad, India
2 Indian Immunologicals Ltd, Hyderabad, India
3 Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore, India
4 University of Hyderabad, Hyderabad, India

Correspondence to: S. Mukhopadhyay; E-mail: sangita{at}cdfd.org.in

Blocking T cell co-stimulatory signals by anti-B7-1/B7-2 mAb is an attractive approach to treat autoimmune diseases. However, anti-B7-1/B7-2 mAb treatment is known to exacerbate autoimmune diseases through mechanisms not fully understood. Tumor necrosis factor alpha (TNF-{alpha}) and reactive oxygen species (ROS) also play important roles in determining the clinical outcome of autoimmune diseases. In this study, we demonstrate that the anti-B7-1 and the anti-B7-2 mAbs activate macrophages for higher induction of TNF-{alpha} and other effector responses such as bacterial cytotoxicity and production of ROS. Nuclear factor-kappaB (NF-{kappa}B) was found to be increased with anti-B7-1/B7-2 mAb treatment. Inhibition of NF-{kappa}B activity by over-expression of phosphorylation-defective I-kappaB alpha in anti-B7-1/B7-2 mAb-treated macrophages decreased TNF-{alpha} production. These data indicate that anti-B7-1 and anti-B7-2 mAbs can trigger innate-effector responses in macrophages by activating NF-{kappa}B-signaling pathway. Our results suggest that the B7 molecules are not only essential for induction of adaptive immune responses but also play roles in activation of innate immune responses.

Keywords: anti-B7-1/B7-2 mAb, autoimmunity, macrophage, NF-kappaB, TNF-alpha

Transmitting editor: M. Feldmann

Received 25 May 2006, accepted 23 January 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.